News

How a VCU professor’s research could help provide Covid-19 therapies

Virginia Commonwealth University is working on the development of a potential treatment for Covid-19.

Michael Peters, Ph.D., a professor in VCU’s Department of Chemical and Life Science Engineering, is leading the research.

Peters said he works everyday in response to the pandemic, which led him to the discovery of a possible lifesaving novel peptide therapeutic that could slow the transmission of Covid-19.

The research caught the attention of biopharmaceutical company Hoth Therapeutics, and recently led to a licensing deal.

“VCU Innovation Gateway and Dr. Peters partnered with Hoth Therapeutics to further develop Dr. Peters’ technology and bring new treatment to the market,” Magdalena Morgan, director of licensing at VCU Innovation Gateway told Inno. “The research is still ongoing but moving forward quickly.”

She added, “Development of new therapeutics is a not an easy and straight forward process, but we remain optimistic that together we can bring this therapy to the market soon.”

Peters said that like vaccines, the primary goal of therapies is to prevent severe illness and death due to Covid.

“This research focuses on understanding how the structure of the virus impacts its ability to attach to human cells,” he said. “This information is necessary for the development of inhibitors that bind to the virus surface to prevent attachment to cells.”

Therapies developed through the research are aimed at treating infected patients by reducing their viral load, which lessens the severity of the virus.

Peters said despite his research, it’s still important for people to get vaccinated to help stop the spread of Covid-19, as well as the emergence of new, and sometimes more dangerous variants.

“Viral variants, such as Delta, are only possible if the virus infects our living cells,” he said. “The virus cannot transform on its own … (It) is not alive any more than a book is alive. If the virus gets inside a cell, the cell, which is alive, reads the book and carries out the book’s instructions.”

“Variants will continue to emerge if we don’t stop the transmission through physical mitigation or vaccination against existing strains,” Peters added.

Morgan said Peters’ research is one of the reasons VCU’s Innovation Gateway is crucial.

“We are the main connection between the amazing research and innovation that is happening at VCU and the commercial partners who have resources to bring those innovations to market to benefit the society,” she said.

Learn more at Richmond Inno.

Recent News

03/21/2023

Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward

03/21/2023

California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference

03/07/2023

RAMP Welcomes 5 Startups into Spring 2023 Cohort

From designing battery electric spotter tractors to developing individualized neuro-oncology treatments for aggressive gliomas, the five companies accepted into RAMP’s Spring 2023 Cohort span the gamut of technology, health science and life science innovation. “We are thrilled to welcome these inspiring entrepreneurs and help them accelerate their vision,” said RAMP director Lisa Garcia. “Not only